OPNT 0.00 Opiant Pharmaceuticals, Inc.
| Range: | 7.34-27.36 | Vol Avg: | 72355 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.83 | Cap: | 0.11B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Jun 04 2007 | Empoloyees: | 37 | ||
| CUSIP: | 683750103 | CIK: | 0001385508 | ISIN: | US6837501039 | Country: | US |
| CEO: | Dr. Roger Crystal M.D. | Website: | https://www.opiant.com | ||||
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow